Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01812954|
Recruitment Status : Completed
First Posted : March 18, 2013
Last Update Posted : August 11, 2017
This study is health economic analysis of medicinal treatment options for moderate-to-severe psoriasis vulgaris from the societal perspective. Efficacy data and other clinical outcomes will be derived from an up-to-date meta-analysis of randomized clinical trials (RCTs) for moderate-to-severe psoriasis. Direct and indirect costs will be extracted from various different sources, including summary of product characteristics (SPCs) and the German S3 guideline on psoriasis care, health care utilization data and official statistics.
The study aims to investigate the comparative cost-effectiveness of biologic and conventional systemic treatments currently (as of June 1st, 2012) approved for moderate-to-severe plaque-type psoriasis in Germany. Effectiveness will be measured by means of the pooled (Psoriasis Area and Severity Index) PASI-75 response rates as reported in RCTs Direct cost as well as indirect cost will be considered.
|Condition or disease||Intervention/treatment|
|Psoriasis||Drug: Methotrexate Drug: Cyclosporins Drug: fumaric acid Drug: Acitretin Drug: Infliximab Drug: etanercept Drug: Adalimumab Drug: Ustekinumab|
|Study Type :||Observational|
|Actual Enrollment :||1 participants|
|Study Start Date :||March 2013|
|Actual Primary Completion Date :||June 2014|
|Actual Study Completion Date :||June 2014|
- Cost per quality-adjusted life year (QALY) gained through treatment with each individual agent compared to supportive care as well as compared to placebo [ Time Frame: 1 year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01812954
|Principal Investigator:||Jochen Schmitt, MD, MPH||University Dresden|